NASDAQ:AVEO AVEO Pharmaceuticals (AVEO) Stock Price, News & Analysis → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free AVEO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$14.99▼$15.0050-Day Range$14.90▼$15.0052-Week Range$3.06▼$15.00Volume247,800 shsAverage Volume601,442 shsMarket Capitalization$521.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get AVEO Pharmaceuticals alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About AVEO Pharmaceuticals Stock (NASDAQ:AVEO)AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Read More Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… AVEO Stock News HeadlinesApril 23, 2024 | msn.comVIDEO: How the Chevrolet Aveo Looks Like in Real-LifeApril 22, 2024 | msn.comWhat does the Chevrolet Aveo Have to offer? The Details You Need to Know if You Live in the United StatesApril 22, 2024 | msn.comFind Out What the New Chevrolet Aveo Interior Has to OfferMarch 28, 2024 | forbes.comKorean Conglomerate LG To Invest $74 Billion In AI, Biotech, Cleantech And Other Growth AreasMarch 28, 2024 | globenewswire.comCORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeMarch 25, 2024 | finanznachrichten.deAVEO Pharmaceuticals, Inc.: AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeMarch 25, 2024 | globenewswire.comAVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeMarch 12, 2024 | finance.yahoo.comNeuroendocrine Tumor Treatment Market revenue to hit USD 8 Billion by 2035, says Research NesterMarch 6, 2024 | msn.com2024 Chevrolet Aveo: Driving The Compact Expat In Mexico CityNovember 30, 2023 | finance.yahoo.comAVEO Oncology, an LG Chem company, Earns Spot on Boston Globe's 2023 Top Places to Work List for Second Consecutive YearNovember 3, 2023 | finance.yahoo.comActinium Appoints Lynn Bodarky as Chief Business OfficerOctober 30, 2023 | afr.comBrookfield finalises $1.45b debt refi for Aveo; lenders pile inJuly 13, 2023 | afr.comBrookfield locks in $1.45b debt refi for Aveo; five banks underwriteMay 10, 2023 | finance.yahoo.comActinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals DayMay 5, 2023 | marketwatch.com2023 Kidney Cancer Market Size Growth Analysis by Absolute Reports | with [101 Pages] and Forecast till 2031May 3, 2023 | marketwatch.comC-MET & HGF Inhibitors Market Growth Opportunities and Emerging Trends till 2031May 3, 2023 | marketwatch.comFGF-2 Inhibitors Market 2023 SWOT Analysis and Demand Status Forecast by 2030April 27, 2023 | marketwatch.comC-MET / HGF Inhibitors Market Size [2023] Global Overview includes Market Trends and Forecast to 2027 | with [148 Pages]April 27, 2023 | marketwatch.comHepatocyte Growth Factor Market Research Analysis 2023-2031April 25, 2023 | marketwatch.comNeuroendocrine Tumors Treatment Market 2023 to 2030 Market Analysis, Share, Size, Trends, Scope, Growth Drivers, By Top Companies And ForecastApril 23, 2023 | marketwatch.com2023-2030 Kidney Cancer Treatment Drugs Market Share, Detailed Examination of Industry Trends and OpportunitiesApril 20, 2023 | marketwatch.comIndustry Research Report on C-MET / HGF Inhibitors Market Share and Industrial Overview till 2030April 16, 2023 | marketwatch.comC-MET / HGF Inhibitors Market Forecast to 2030April 14, 2023 | msn.com2024 Chevy Aveo: The Sonic Is Still Alive and Thriving, Just Not in the U.S.April 12, 2023 | marketwatch.comC-MET & HGF Inhibitors Market Growth by 2030See More Headlines Receive AVEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today6/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:AVEO CUSIP05358810 CIK1325879 Webwww.aveooncology.com Phone(617) 400-0101Fax617-995-4995Employees114Year Founded2001Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,340,000.00 Net Margins-30.79% Pretax Margin-30.79% Return on Equity-81.66% Return on Assets-28.83% Debt Debt-to-Equity Ratio0.94 Current Ratio2.37 Quick Ratio2.35 Sales & Book Value Annual Sales$42.29 million Price / Sales12.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book11.28Miscellaneous Outstanding Shares34,763,000Free Float33,619,000Market Cap$521.45 million OptionableOptionable Beta1.00 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMichael P. BaileyPresident, Chief Executive Officer & DirectorJebediah LedellChief Operating OfficerErick J. LuceraChief Financial OfficerMatthew CoulterVice President-Information TechnologyStefanie SolomonHead-ComplianceKey CompetitorsMyriad GeneticsNASDAQ:MYGNDynavax TechnologiesNASDAQ:DVAXLigand PharmaceuticalsNASDAQ:LGNDBioCryst PharmaceuticalsNASDAQ:BCRXMannKindNASDAQ:MNKDView All Competitors AVEO Stock Analysis - Frequently Asked Questions How were AVEO Pharmaceuticals' earnings last quarter? AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) released its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. The biopharmaceutical company earned $15.17 million during the quarter, compared to analyst estimates of $14.29 million. AVEO Pharmaceuticals had a negative trailing twelve-month return on equity of 81.66% and a negative net margin of 30.79%. During the same period last year, the company posted ($0.33) EPS. When did AVEO Pharmaceuticals' stock split? AVEO Pharmaceuticals shares reverse split before market open on Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Tuan Ha-Ngoc's approval rating as AVEO Pharmaceuticals' CEO? 4 employees have rated AVEO Pharmaceuticals Chief Executive Officer Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among the company's employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at AVEO Pharmaceuticals to a friend. What other stocks do shareholders of AVEO Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA). This page (NASDAQ:AVEO) was last updated on 6/7/2024 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s...Weiss Ratings | SponsoredMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVEO Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AVEO Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.